216 related articles for article (PubMed ID: 35367910)
21. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG; Ramalingam SS; Ciuleanu TE; Lee JS; Urban L; Caro RB; Park K; Sakai H; Ohe Y; Nishio M; Audigier-Valette C; Burgers JA; Pluzanski A; Sangha R; Gallardo C; Takeda M; Linardou H; Lupinacci L; Lee KH; Caserta C; Provencio M; Carcereny E; Otterson GA; Schenker M; Zurawski B; Alexandru A; Vergnenegre A; Raimbourg J; Feeney K; Kim SW; Borghaei H; O'Byrne KJ; Hellmann MD; Memaj A; Nathan FE; Bushong J; Tran P; Brahmer JR; Reck M
J Thorac Oncol; 2022 Feb; 17(2):289-308. PubMed ID: 34648948
[TBL] [Abstract][Full Text] [Related]
22. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
[TBL] [Abstract][Full Text] [Related]
23. First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.
Yang L; Song X; Zeng W; Zheng Z; Lin W
Orphanet J Rare Dis; 2023 Oct; 18(1):326. PubMed ID: 37845696
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life results from the phase III CheckMate 067 study.
Schadendorf D; Larkin J; Wolchok J; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao C; Wagstaff J; Callahan MK; Postow MA; Smylie M; Ferrucci PF; Dummer R; Hill A; Taylor F; Sabater J; Walker D; Kotapati S; Abernethy A; Long GV
Eur J Cancer; 2017 Sep; 82():80-91. PubMed ID: 28651159
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
Nakamura A; Hashimoto M; Kondo N; Matsumoto S; Kuroda A; Minami T; Kitajima K; Kuribayashi K; Kijima T; Hasegawa S
Int J Clin Oncol; 2023 Mar; 28(3):409-415. PubMed ID: 36609928
[TBL] [Abstract][Full Text] [Related]
26. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Reck M; Ciuleanu TE; Lee JS; Schenker M; Zurawski B; Kim SW; Mahave M; Alexandru A; Peters S; Pluzanski A; Caro RB; Linardou H; Burgers JA; Nishio M; Martinez-Marti A; Azuma K; Axelrod R; Paz-Ares LG; Ramalingam SS; Borghaei H; O'Byrne KJ; Li L; Bushong J; Gupta RG; Grootendorst DJ; Eccles LJ; Brahmer JR
J Thorac Oncol; 2023 Aug; 18(8):1055-1069. PubMed ID: 37146754
[TBL] [Abstract][Full Text] [Related]
27. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
Reck M; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Reyes F; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; Paz-Ares L; Carbone DP; Memaj A; Marimuthu S; Zhang X; Tran P; John T
ESMO Open; 2021 Oct; 6(5):100273. PubMed ID: 34607285
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab for the treatment of unresectable pleural mesothelioma.
Hotta K; Fujimoto N; Kozuki T; Aoe K; Kiura K
Expert Opin Biol Ther; 2020 Feb; 20(2):109-114. PubMed ID: 31825692
[No Abstract] [Full Text] [Related]
29. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K; Ajani JA; Moehler M; Garrido M; Gallardo C; Shen L; Yamaguchi K; Wyrwicz L; Skoczylas T; Bragagnoli AC; Liu T; Tehfe M; Elimova E; Bruges R; Zander T; de Azevedo S; Kowalyszyn R; Pazo-Cid R; Schenker M; Cleary JM; Yanez P; Feeney K; Karamouzis MV; Poulart V; Lei M; Xiao H; Kondo K; Li M; Janjigian YY
Nature; 2022 Mar; 603(7903):942-948. PubMed ID: 35322232
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.
Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F
Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
32. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
33. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC; Vellanki PJ; Larkins E; Chatterjee S; Mishra-Kalyani PS; Bi Y; Qosa H; Liu J; Zhao H; Biable M; Hotaki LT; Shen YL; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2022 Feb; 28(3):446-451. PubMed ID: 34462287
[TBL] [Abstract][Full Text] [Related]
34. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS
ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials.
Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H
EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791
[TBL] [Abstract][Full Text] [Related]
37. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].
Laune Q; Brosseau S
Bull Cancer; 2022 Jan; 109(1):4-6. PubMed ID: 34654542
[No Abstract] [Full Text] [Related]
38. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
[TBL] [Abstract][Full Text] [Related]
39. Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.
Barbier MC; Fengler A; Pardo E; Bhadhuri A; Meier N; Gautschi O
Pharmacoeconomics; 2023 Dec; 41(12):1641-1655. PubMed ID: 37572261
[TBL] [Abstract][Full Text] [Related]
40. Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.
Cancer Discov; 2017 Aug; 7(8):OF7. PubMed ID: 28592400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
